MedTrace Logo

Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China(STAT)

NCT05906459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2023-07-17

No results posted yet for this study

Summary

The present study aims to establish a " one-sample testing platform " and assess the prevalence of hepatitis C in individuals taking routine physical examination or outpatient visit in mainland China.

Conditions

  • Hepatitis C Virus Infection

Interventions

DIAGNOSTIC_TEST

Anti-HCV antibody and HCV core antigen testing

HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings. For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • WenHong Zhang, M.D. · Huashan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-26
Primary Completion
2023-12-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05906459 on ClinicalTrials.gov